Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tipifarnib with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma Multiforme
NCT02227901Phase 1Completed
- Sponsor
- National Cancer Institute
- Start
- Sep 2002
- Primary completion
- Jun 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tipifarnib in glioblastoma multiforme (GBM) and Gliosarcoma (GS), sponsored by National Cancer Institute. Primary endpoints: Dose Limiting Toxicity at 10 weeks and Maximum Tolerated Dose at 10 weeks. Started Sep 2002; status: completed.
02
Drugs
tipifarnib
03
Conditions
glioblastoma multiforme (GBM)Gliosarcoma (GS)
Beyond the preview
Go deeper on NCT02227901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02227901.